Oxis Turbuhaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbuhaler, is a long‑acting β2‑adrenergic agonist (LABA) presented as a dry powder inhaler for inhalation use. It provides bronchodilation for the management of asthma and chronic obstructive pulmonary disease (COPD) in adult patients.

GNH USA supplies Oxis Turbuhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and offers regulatory support for global distribution of the product continually across multiple regions.

Formoterol fumarate dihydrate is a long‑acting β2‑adrenergic agonist used to manage airway obstruction in chronic respiratory diseases.

Asthma: provides long‑term bronchodilation to control symptoms and reduce exacerbations. Chronic obstructive pulmonary disease (COPD): improves airflow and reduces the frequency of COPD exacerbations. Maintenance therapy for reversible airway obstruction: offers sustained bronchodilation as part of a step‑wise treatment plan.

Formoterol may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Tremor: mild shaking of the hands or limbs. - Headache: transient headache episodes. - Throat irritation: discomfort or soreness in the throat. - Cough: occasional dry cough after inhalation. - Palpitations: sensation of rapid or irregular heartbeat. - Muscle cramps: occasional leg or calf cramps.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Tachyarrhythmia: rapid heart rhythm that may require medical attention. - Hypersensitivity reactions: rash, itching, or swelling. - Angioedema: swelling of face, lips, tongue, or throat. - Severe allergic reaction: anaphylaxis requiring emergency care.

When prescribing or using Formoterol, consider the following safety measures.

Assess cardiovascular status: evaluate for arrhythmias before initiating therapy. Avoid use as monotherapy in asthma: always combine with an inhaled corticosteroid. Monitor for worsening asthma symptoms: ensure the patient has a rescue inhaler available. Use with caution in patients with severe COPD: adjust therapy based on clinical response. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Formoterol can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): increased risk of cardiovascular events. - Other long‑acting β2‑agonists: additive risk of tachycardia and tremor.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate hypokalemia, requiring electrolyte monitoring. - Theophylline: potential increase in side‑effects such as nausea or palpitations. - Inhaled corticosteroids: may increase systemic exposure to formoterol, warranting dose review.